Ingen Files Annual Financial and Disclosure Ending May 31, 2009


YUCAIPA, Calif., June 24, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT) a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing ageing population and emerging markets for Home (DME), Hospital and Aviation Industries announced today that as a requirement with FINRA and the Pink OTC markets, the company has filed the annual financial and disclosure statement ending may 31, 2009. This was filed on June 23, 2009.

After a review of the information posted to pinksheets.com, the Pink OTC Markets determined that Ingen continues to meet the requirements for the Current Information tier for the period ending 05/31/2009. The company will remain in the Current Information tier until the next period end date review in September-2009.

"The company continues to comply with our reporting obligations as a part of our growth plan to return as a fully reporting company during our fiscal calendar year. The plan is to file Form 10 to return as a reporting company under Rule 12g. Once filed, the company has already completed a full SEC review in December 2008, and FINRA had already notified our Market Maker that we would qualify to list on the OTC-Bulletin Board. Our auditing firm is prepared and ready to assist with the 10-QSB and 10-KSB filings based upon our current filings with Pink OTC Markets," stated Thomas J. Neavit, Chief Financial Officer.

About Ingen/Oxyview:

Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472

www.ingen-tech.com

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.



            

Contact Data